258 related articles for article (PubMed ID: 24441096)
1. Alternative activation of human plasmacytoid DCs in vitro and in melanoma lesions: involvement of LAG-3.
Camisaschi C; De Filippo A; Beretta V; Vergani B; Villa A; Vergani E; Santinami M; Cabras AD; Arienti F; Triebel F; Rodolfo M; Rivoltini L; Castelli C
J Invest Dermatol; 2014 Jul; 134(7):1893-1902. PubMed ID: 24441096
[TBL] [Abstract][Full Text] [Related]
2. Plasmacytoid dendritic cells in melanoma: can we revert bad into good?
Di Domizio J; Demaria O; Gilliet M
J Invest Dermatol; 2014 Jul; 134(7):1797-1800. PubMed ID: 24924760
[TBL] [Abstract][Full Text] [Related]
3. LAG-3 regulates plasmacytoid dendritic cell homeostasis.
Workman CJ; Wang Y; El Kasmi KC; Pardoll DM; Murray PJ; Drake CG; Vignali DA
J Immunol; 2009 Feb; 182(4):1885-91. PubMed ID: 19201841
[TBL] [Abstract][Full Text] [Related]
4. Collapse of the Plasmacytoid Dendritic Cell Compartment in Advanced Cutaneous Melanomas by Components of the Tumor Cell Secretome.
Vescovi R; Monti M; Moratto D; Paolini L; Consoli F; Benerini L; Melocchi L; Calza S; Chiudinelli M; Rossi G; Bugatti M; Maio M; Fonsatti E; Farisoglio C; Simbolo M; Almici C; Verardi R; Scarpa A; Bergese P; Manganoni A; Facchetti F; Vermi W
Cancer Immunol Res; 2019 Jan; 7(1):12-28. PubMed ID: 30401679
[TBL] [Abstract][Full Text] [Related]
5. Plasmacytoid dendritic cells support melanoma progression by promoting Th2 and regulatory immunity through OX40L and ICOSL.
Aspord C; Leccia MT; Charles J; Plumas J
Cancer Immunol Res; 2013 Dec; 1(6):402-15. PubMed ID: 24778133
[TBL] [Abstract][Full Text] [Related]
6. MHC class II engagement by its ligand LAG-3 (CD223) contributes to melanoma resistance to apoptosis.
Hemon P; Jean-Louis F; Ramgolam K; Brignone C; Viguier M; Bachelez H; Triebel F; Charron D; Aoudjit F; Al-Daccak R; Michel L
J Immunol; 2011 May; 186(9):5173-83. PubMed ID: 21441454
[TBL] [Abstract][Full Text] [Related]
7. Imiquimod clears tumors in mice independent of adaptive immunity by converting pDCs into tumor-killing effector cells.
Drobits B; Holcmann M; Amberg N; Swiecki M; Grundtner R; Hammer M; Colonna M; Sibilia M
J Clin Invest; 2012 Feb; 122(2):575-85. PubMed ID: 22251703
[TBL] [Abstract][Full Text] [Related]
8. Impaired activation of plasmacytoid dendritic cells
Monti M; Ferrari G; Grosso V; Missale F; Bugatti M; Cancila V; Zini S; Segala A; La Via L; Consoli F; Orlandi M; Valerio A; Tripodo C; Rossato M; Vermi W
Front Immunol; 2023; 14():1227648. PubMed ID: 38239354
[TBL] [Abstract][Full Text] [Related]
9. Human Plasmacytoid Dendritic Cells and Cutaneous Melanoma.
Monti M; Consoli F; Vescovi R; Bugatti M; Vermi W
Cells; 2020 Feb; 9(2):. PubMed ID: 32054102
[TBL] [Abstract][Full Text] [Related]
10. Plasmacytoid dendritic cell role in cutaneous malignancies.
Saadeh D; Kurban M; Abbas O
J Dermatol Sci; 2016 Jul; 83(1):3-9. PubMed ID: 27236509
[TBL] [Abstract][Full Text] [Related]
11. Plasmacytoid dendritic cells, a role in neoplastic prevention and progression.
Lombardi VC; Khaiboullina SF; Rizvanov AA
Eur J Clin Invest; 2015 Jan; 45 Suppl 1():1-8. PubMed ID: 25524580
[TBL] [Abstract][Full Text] [Related]
12. Lymphocyte activation gene-3 (LAG-3, CD223) in plasmacytoid dendritic cells (pDCs): a molecular target for the restoration of active antitumor immunity.
Castelli C; Triebel F; Rivoltini L; Camisaschi C
Oncoimmunology; 2014 Nov; 3(11):e967146. PubMed ID: 25941596
[TBL] [Abstract][Full Text] [Related]
13. Rapamycin has suppressive and stimulatory effects on human plasmacytoid dendritic cell functions.
Boor PP; Metselaar HJ; Mancham S; van der Laan LJ; Kwekkeboom J
Clin Exp Immunol; 2013 Dec; 174(3):389-401. PubMed ID: 23968562
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant Radiochemotherapy Significantly Alters the Phenotype of Plasmacytoid Dendritic Cells and 6-Sulfo LacNAc
Wagner F; Hölig U; Wilczkowski F; Plesca I; Sommer U; Wehner R; Kießler M; Jarosch A; Flecke K; Arsova M; Tunger A; Bogner A; Reißfelder C; Weitz J; Schäkel K; Troost EGC; Krause M; Folprecht G; Bornhäuser M; Bachmann MP; Aust D; Baretton G; Schmitz M
Front Immunol; 2019; 10():602. PubMed ID: 30984181
[TBL] [Abstract][Full Text] [Related]
15. Human pDCs Are Superior to cDC2s in Attracting Cytolytic Lymphocytes in Melanoma Patients Receiving DC Vaccination.
van Beek JJP; Flórez-Grau G; Gorris MAJ; Mathan TSM; Schreibelt G; Bol KF; Textor J; de Vries IJM
Cell Rep; 2020 Jan; 30(4):1027-1038.e4. PubMed ID: 31995747
[TBL] [Abstract][Full Text] [Related]
16. Characterization of circulating dendritic cells in melanoma: role of CCR6 in plasmacytoid dendritic cell recruitment to the tumor.
Charles J; Di Domizio J; Salameire D; Bendriss-Vermare N; Aspord C; Muhammad R; Lefebvre C; Plumas J; Leccia MT; Chaperot L
J Invest Dermatol; 2010 Jun; 130(6):1646-56. PubMed ID: 20220766
[TBL] [Abstract][Full Text] [Related]
17. HMGB1 secretion during cervical carcinogenesis promotes the acquisition of a tolerogenic functionality by plasmacytoid dendritic cells.
Demoulin S; Herfs M; Somja J; Roncarati P; Delvenne P; Hubert P
Int J Cancer; 2015 Jul; 137(2):345-58. PubMed ID: 25492101
[TBL] [Abstract][Full Text] [Related]
18. Recruitment of immature plasmacytoid dendritic cells (plasmacytoid monocytes) and myeloid dendritic cells in primary cutaneous melanomas.
Vermi W; Bonecchi R; Facchetti F; Bianchi D; Sozzani S; Festa S; Berenzi A; Cella M; Colonna M
J Pathol; 2003 Jun; 200(2):255-68. PubMed ID: 12754747
[TBL] [Abstract][Full Text] [Related]
19. The cytokine milieu compromises functional capacity of tumor-infiltrating plasmacytoid dendritic cells in HPV-negative but not in HPV-positive HNSCC.
Koucký V; Hladíková K; Táborská E; Bouček J; Grega M; Špíšek R; Fialová A
Cancer Immunol Immunother; 2021 Sep; 70(9):2545-2557. PubMed ID: 33569630
[TBL] [Abstract][Full Text] [Related]
20. Human Plasmacytoid and Monocyte-Derived Dendritic Cells Display Distinct Metabolic Profile Upon RIG-I Activation.
Fekete T; Sütö MI; Bencze D; Mázló A; Szabo A; Biro T; Bacsi A; Pazmandi K
Front Immunol; 2018; 9():3070. PubMed ID: 30622542
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
